Key Takeaways MIRM enrolls first patient in phase II BLOOM study on MRM-3379 for patients with Fragile X syndrome.The BLOOM study will assess safety, tolerability and clinical benefit of MRM-3379 in male patients.Top-line data from the phase II study is expected in 2027. Currently, no therapies are approved for FXS.Mirum Pharmaceuticals (MIRM) announced that it has enrolled the first patient in the phase II BLOOM study evaluating its newly in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndro ...